Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice | Zendy

Richard D. Gordon | Zendy; Eduardo A. Albornoz | Zendy; Daniel C. Christie | Zendy; Monica R. Langley | Zendy; Vinod Kumar | Zendy; Susanna Mantovani | Zendy; Avril A. B. Robertson | Zendy; Mark S. Butler | Zendy; Dominic B. Rowe | Zendy; Luke O'neill | Zendy; Anumantha G. Kanthasamy | Zendy; Kate Schroder | Zendy; Matthew A. Cooper | Zendy; Trent M. Woodruff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

Author(s) -

Richard D. Gordon,

Eduardo A. Albornoz,

Daniel C. Christie,

Monica R. Langley,

Vinod Kumar,

Susanna Mantovani,

Avril A. B. Robertson,

Mark S. Butler,

Dominic B. Rowe,

Luke O'neill,

Anumantha G. Kanthasamy,

Kate Schroder,

Matthew A. Cooper,

Trent M. Woodruff

Publication year - 2018

Publication title -

science translational medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.819

H-Index - 216

eISSN - 1946-6242

pISSN - 1946-6234

DOI - 10.1126/scitranslmed.aah4066

Subject(s) - inflammasome , substantia nigra , neuroinflammation , neurodegeneration , dopaminergic , microglia , pyrin domain , pyroptosis , parkinson's disease , neuroscience , microbiology and biotechnology , caspase 1 , alpha synuclein , chemistry , biology , medicine , pathology , immunology , inflammation , dopamine , disease

Oral treatment with a brain-penetrant NLRP3 inhibitor has protective effects in preclinical models of Parkinson’s disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research